Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
The event will feature the participation of John O'Keefe, British-American neuroscientist and psychologist who, in 2014, together with Edvard Moser and May Britt received the Nobel Prize in Medicine. The wonders of the brain and neuroscience at UNAB, Universidad Autónoma de Bucaramanga, Colombia.
Scientists at the Maharaja Sayajirao University of Baroda's biochemistry department put up a systematic review on three plant derivatives that soothes eczema symptoms.
An advisory to the US Food and Drug Administration unanimously voted last week, authorization of a booster jab, a third dose that is, of mRNA vaccine of Moderna, and second for Johnson & Johnson's.
A new draft recommendation released by the US Preventive Services Task Force states that its current evidence is not enough for evaluating screening for eating disorders among adults and adolescents.
Researchers developed a new mathematical model that shows transfusion of blood substitutes could treat anemic patients and be more readily available, solving global blood shortages.
A new study finding recently showed that as much as 90 percent of tuberculosis bacteria released from an infected individual may be carried in droplets also known as aerosols that are expelled when one breathes out deeply.
Several years ago, a teenage boy injected himself with mercury, believing he'd be able to develop superpowers similar to his favorite characters from the X-Men movie.